---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-26-000007"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:30:23.530209+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways: Phase 3 COMP006 meets primary endpoint; COMP360 25mg shows -3.8 point MADRS reduction (p<0.001)

## Summary
- COMP006: Two 25mg doses vs 1mg showed -3.8 point MADRS reduction (p<0.001) at Week 6, meeting primary endpoint.
- 39% of COMP006 25mg arm achieved clinically meaningful reduction (≥25% MADRS) at Week 6.
- COMP005 single dose previously showed -3.6 point difference (p<0.001); durable effect through Week 26 after 1-2 doses.
- Safety profile: TEAEs mostly mild/moderate, resolving within 24h; SAE suicidal ideation <1% across both trials.
- Company requested FDA meeting to discuss rolling NDA submission for COMP360 in treatment-resistant depression.

## SEC filing metadata
- accession: 0001816590-26-000007
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/0001816590-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-26-000007
- JSON: https://secwatch.observer/filing/0001816590-26-000007.json
- Plain text: https://secwatch.observer/filing/0001816590-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.